AnalystsDewey SteadmanDewey Steadman's Stock Forecasts
AnalystsDewey Steadman
Sectors:
Analyst Ranking
Bottom 14%
#4245 out of 4870 analysts
Average Return
-7.17%
Win Rate
35%6 out of 17
Risk vs Reward
Poor
Good
Dewey Steadman's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Savara IncSVRA | +86.53% | $5.05 | $9.42 | 2017-06-07 - 2018-06-07 | Strong Buy |
Ani Pharmaceuticals IncANIP | +37.39% | $48.73 | $66.95 | 2017-07-31 - 2018-07-31 | Strong Buy |
Ani Pharmaceuticals IncANIP | +21.50% | $56.41 | $68.54 | 2018-08-17 - 2019-08-16 | Strong Buy |
Ani Pharmaceuticals IncANIP | +10.44% | $52.47 | $57.95 | 2018-11-12 - 2019-11-12 | Strong Buy |
Perrigo Co PLCPRGO | +3.54% | $84.09 | $87.07 | 2017-02-22 - 2018-02-22 | Strong Buy |
Dewey Steadman Analyst Color
Get additional color on Dewey Steadman's coverage of popular stocks
Dewey Steadman's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Teligent IncTLGT | 4 | Hold | $2.60 | N/A | Maintains | 6 years ago |
Ani Pharmaceuticals IncANIP | 5 | Strong Buy | $70.00 | N/A | Maintains | 6 years ago |
Endo International PLCENDPQ | 4 | Strong Buy | $20.00 | N/A | Upgrades | 6 years ago |
Pacira Biosciences IncPCRX | 10 | Hold | $49.00 | N/A | Maintains | 7 years ago |
Amneal Pharmaceuticals IncAMRX | 1 | Hold | $21.00 | N/A | Maintains | 7 years ago |
Zevra Therapeutics IncZVRA | 1 | Strong Buy | $11.00 | N/A | Maintains | 7 years ago |
Adicet Bio IncACET | 3 | Strong Buy | $91.00 | N/A | Maintains | 7 years ago |
Savara IncSVRA | 2 | Strong Buy | $25.00 | N/A | Maintains | 8 years ago |
Perrigo Co PLCPRGO | 2 | Strong Buy | $100.00 | N/A | Maintains | 8 years ago |
Impax Laboratories IncIPXL | 1 | Hold | $19.00 | N/A | Initiates Coverage On | 8 years ago |
Lipocine IncLPCN | 2 | Strong Buy | $255.00 | N/A | Assumes | 8 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.